WHO strategy for collecting safety data in public health programmes: Complementing spontaneous reporting systems

Drug Safety

Volumn 36, Issue 2, 2013, Pages 75-81

  Pal, Shanthi N ^a   Duncombe, Chris ^b   Falzon, Dennis ^a   Olsson, Sten ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

^c UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DEMOGRAPHY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MEDICAL RECORD; MEDICATION ERROR; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; TREATMENT DURATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTITUDE OF HEALTH PERSONNEL; DRUG MONITORING; DRUG TOXICITY; HEALTH PERSONNEL; HUMANS; PHARMACOVIGILANCE; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84876527613     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-012-0014-6     Document Type: Article

References (23)

1. WHO. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002.
2. Pal S, Dodoo A, Mantel A, et al. Pharmacovigilance and safety of medicines. In: WHO, editor. The world medicines situation 2011. Geneva: WHO; 2011.
3. Sharma M, Gupta SK. Postmarketing surveillance. In: Gupta SK, editor. Textbook of pharmacovigilance. New Delhi: Jaypee Brothers; 2011. p. 75-92.
4. Alj L, Touzani MDW, Benkirane R, et al. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med. 2007;19(4):187-94.
5. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743-52.
6. Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf. 2006;29(2):175-81.
7. WHO. WHO international drug monitoring: cerivastatin and gemfibrozil. WHO Drug Info. 2002;16(2):8-11.
8. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385-96.
9. Olsson S, Pal S, Stergachis A, et al. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689-703.
10. WHO. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: WHO; 2006.
11. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2010 version). Geneva: WHO; 2010.
12. WHO. Treatment of tuberculosis: guidelines, 4th edn. Geneva: WHO; 2010.
13. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28.
14. Dodoo A, Adjei S, Couper M, et al. When rumours derail a mass deworming exercise. Lancet. 2007;370:465-6.
15. Global Fund to Fight AIDS, TB and Malaria. The Global Fund strategy 2012-2016: investing for impact. Geneva: Global Fund to Fight AIDS, TB and Malaria; 2012.
16. WHO. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: WHO; 2008.
17. WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. Geneva: WHO; 2009.
18. Coulter DM. The development of prescription event monitoring in the New Zealand Intensive Medicines Monitoring Programme. In: Mann R, Andrews EB, editors. Pharmacovigilance. Chichester: Wiley; 2002. p. 345-62.
19. Shakir SAW. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: Wiley; 2005. p. 337-46.
20. Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for epidemiological studies. Geneva: CIOMS; 2009.
21. WHO. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis. Geneva: WHO; 2012.
22. Clarkson A, Ingleby E, Choonara I, et al. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child. 2001;84(4):337-9.
23. Mehta U, Durheim D, Mabuza A, et al. Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga province, South Africa. Drug Saf. 2007;30(10):899-910.